European payer organizations and health technology appraisal (HTA) bodies have warned that the European Commission’s overhaul of the EU pharmaceutical legislation should not lead to faster marketing approval mechanisms. This would exacerbate existing problems for pricing and reimbursement decision makers caused by an increasing trend for regulatory approvals based on limited evidence, said speakers at a recent online event.
The solutions to the “uncertainty problem” could lie in greater collaboration between payers, HTAs and regulators at an earlier stage...
